NRXP

$3.34-$0.02 (-0.60%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$143.8M

43M shares

52-week range

$1.62 – $5.06

50% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-139.16

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$10M	-13.7%	$-0.38	$-0.45–$-0.29	—	2
2027	$179M	+1657.7%	$0.30	$0.26–$0.34	11.0×	2
2028	$499M	+178.4%	$2.49	$1.50–$4.11	1.3×	1
2029	$745M	+49.4%	$4.51	$2.72–$7.44	0.7×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-15	$-0.05	$-0.04	+20.0%
2026-03-23	$-0.09	$0.19	+311.1%
2025-11-14	$-0.11	$-0.18	-63.6%
2025-08-18	$-0.15	$-0.98	-552.7%
2025-05-15	$-0.30	$-0.34	-13.3%
2025-03-14	$-0.20	$-0.30	-50.0%
2024-11-14	$-0.81	$-0.15	+81.5%
2024-08-14	$-0.81

DCF fair valuemodel estimate

Intrinsic value

$0.71

Price

$3.34

Implied downside

-79%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NRXPNRx Pharmaceuticals, Inc.	$3.34	-0.60%	$58M	—
COEPCoeptis Therapeutics Holdings, Inc.	$10.99	-8.57%	$39M	—
CUECue Biopharma, Inc.	$31.08	+2.17%	$82M	—
EQEquillium, Inc.	$2.01	-7.80%	$127M	—
HOWLWerewolf Therapeutics, Inc.	$0.39	+1.07%

NRX Pharmaceuticals, Inc. Common Stock

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

nrxpharma.com

Employees: 29
IPO / List date: May 25, 2021
HQ: WILMINGTON, DE

Held by traders on TradeandTell

No one on the platform currently holds NRXP.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-09-30	128,175	$423.0K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2024-04-02	1-for-10reverse

Recent trades on TradeandTell

No one on the platform has traded NRXP yet.

$NRXP chatter on StockTwits

Founder V@FounderVBullish3h
$NRXP Finally...
View on StockTwits ↗
Aura@ExploringTradesBullish9h
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $NRXP $CISS
View on StockTwits ↗
mary@mary469h
$NRXP 4 dollars tommorow
View on StockTwits ↗
Allan Tamshen@RedDoggProductions10h
$NRXP 🧠 The NDA Pathway: Suicidal Depression & Severe MDDNRx Pharmaceuticals has cleared major regulatory hurdles for NRX-100 (intravenous ketamine) to treat severe depression with acute suicidality:No New Clinical Trials Required: Following a pivotal Type C meeting, the FDA agreed to review existing clinical trial data as substantial evidence of efficacy.Real-World Evidence Backing: The FDA approved a protocol allowing NRx to use real-world data from Osmind as confirmatory evidence. This heavily de-risks the application process.Expanded Indication: Based on FDA guidance, the company expanded its proposed drug label from strictly suicidal patients to the much larger population of patients suffering from treatment-resistant depression who may experience suicidality.Timeline: NRx targeted their formal NDA submission window for mid-2026, aiming to lock in a late 2026/early 2027 PDUFA date.
View on StockTwits ↗
Braxton@Braxton1413h
$NRXP finally hit my goal of 3500 shares need 7 dollars now
View on StockTwits ↗
sa@Saqer991Bullish14h
$NRXP I believe that when ketamine is approved, we will see a significant price increase above $7, because the FDA will intensify its efforts to stop the sale of unlicensed ketamine… Be optimistic
View on StockTwits ↗
Jenga Master@jonny80s15h
$NRXP the pump and dumps to the $3.60 range are entertaining. Expect more of the same till management gets their shit together.
View on StockTwits ↗
Discovery01@Discovery01Bullish15h
$NRXP Acquisition potential!
View on StockTwits ↗
Mac16@Tide16Bullish16h
$NRXP
View on StockTwits ↗
D Castle@Dcastle16h
$NRXP Here we go getting ready to break 2nd support of 3.59
View on StockTwits ↗
Jenga Master@jonny80s17h
$NRXP short percentage didn’t increase that much as of July 31st. Currently 19.57% with 6.55M shares. They certainly didn’t cover heading into the GDUFA, which means……. They are expecting more headwinds for NRXP going forward. No one knows how long the revised GDUFA date will be delayed best scenario 3 months worst case 9 months. Q2 due next week. Javitt will have to explain why all his catalysts for q2 failed miserably and why there has been zero progress halfway through q3.
View on StockTwits ↗
Gus Alexander@gus_trades17h
$NRXP price to borrow shorts finally jumped above 7% trading above vwap ema9 and ema21, POC is up 5 cents from yesterdays close, weve already broken resistance at 3.50 gone back down and back up to 3.52 touching 3.54 briefly. hoping for 1.5M in volume (but the volume so far doesnt support this, and closing above 3.50 before the day. big day for us
View on StockTwits ↗
Alfred Gick@fuctonfauci1d
$NRXP It looks like value is once again being created for loyal long-term shareholders. "not June 2026, June 2027" ...
View on StockTwits ↗
Robert J Tobin@RobZEBRABullish1d
$NRXP the charts?
View on StockTwits ↗
Beef eater@Ketasniffer1d
$NRXP when is earnings call?
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.